- Heuer, Hilary W
- Wang, P
- Rascovsky, K
- Wolf, A
- Appleby, B
- Bove, J
- Bordelon, Y
- Brannelly, P
- Brushaber, DE
- Caso, C
- Coppola, G
- Dickerson, B
- Dickinson, S
- Domoto-Reilly, K
- Faber, K
- Ferrall, J
- Fields, J
- Fishman, A
- Fong, J
- Foroud, T
- Forsberg, LK
- Gearhart, D
- Ghazanfari, B
- Ghoshal, N
- Goldman, J
- Graff-Radford, J
- Graff-Radford, N
- Grant, I
- Grossman, M
- Haley, D
- Hsiung, G-Y
- Huey, E
- Irwin, D
- Jones, D
- Kantarci, K
- Karydas, A
- Kaufer, D
- Kerwin, D
- Knopman, D
- Kornak, J
- Kramer, JH
- Kraft, R
- Kremers, WK
- Kukull, W
- Litvan, I
- Ljubenkov, P
- Mackenzie, IR
- Maldonado, M
- Manoochehri, M
- McGinnis, S
- McKinley, E
- Mendez, MF
- Miller, BL
- Onyike, C
- Pantelyat, A
- Pearlman, R
- Petrucelli, L
- Potter, M
- Rademakers, R
- Ramos, EM
- Rankin, KP
- Roberson, ED
- Rogalski, E
- Sengdy, P
- Shaw, L
- Syrjanen, J
- Tartaglia, MC
- Tatton, N
- Taylor, J
- Toga, A
- Trojanowski, J
- Weintraub, S
- Wong, B
- Wszolek, Z
- Boeve, BF
- Rosen, HJ
- Boxer, AL
- ARTFL and LEFFTDS consortia
- et al.
Introduction
Behavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments.Methods
A total of 135 sporadic (s-bvFTD; mean age 63.3 years; 34% female) and 99 familial (f-bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f-bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule-associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation.Results
Participants with f-bvFTD were younger and had earlier age at onset. s-bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI-Q) scores due to more frequent endorsement of depression and irritability.Discussion
f-bvFTD and s-bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.